Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND)

Vyome (NASDAQ:HIND) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vyome and Profusa, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1	0	2	0	2.33
Profusa	1	0	0	0	1.00

Vyome presently has a consensus target price of $15.00, suggesting a potential upside of 224.68%. Given Vyome’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vyome is more favorable than Profusa.

Profitability

This table compares Vyome and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-423.39%	-166.02%
Profusa	N/A	N/A	N/A

Volatility & Risk

Vyome has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Profusa has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500.

Valuation and Earnings

This table compares Vyome and Profusa”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$8.01 million	3.25	-$7.13 million	($125.20)	-0.04
Profusa	N/A	N/A	N/A	N/A	N/A

Profusa has lower revenue, but higher earnings than Vyome.

Institutional and Insider Ownership

22.1% of Vyome shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 21.6% of Profusa shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vyome beats Profusa on 7 of the 10 factors compared between the two stocks.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.